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Leukemia has long been recognized as one of the seri-
ous diseases. The number of new cases worldwide in
2007 was projected to be 330,963, with an estimated
245,871 deaths [1]. Undoubtedly, there is an urgent
need for novel therapeutic agents for effective treat-
ment of leukemia. One of the effective approaches in
searching for new drugs is to synthesize new deriva-
tives of naturally existing chemicals by modification
of their structural skeleton.
Tricyclic β-carboline alkaloids are well-known nat-
ural alkaloids that are found in various plants [2],
marine creatures [3], insects [4], and mammalian as
well as human tissues and body fluids [5,6]. These
alkaloids are of great interest due to their diverse bio-
logical activities [7]. Since Ishida and coworkers [8]
reported in 1999 that harmine, a β-carboline alkaloid,
and its analogs significantly inhibit drug-resistant 
KB cells, a lot of research on the anticancer activity of
β-carboline derivatives has been reported [9–13]. How-
ever, research on the anticancer activity of tricyclic 
α-carboline (pyrido[2,3-b]indole) derivatives has been
relatively rare [14–16].
In the present study, we investigated the anticancer
activity of new tricyclic α-carbolines. We selected α-
carboline as the basic scaffold and synthesized a
series of its 1,6,8,9-substituted derivatives for cyto-
toxicity evaluation against the HL-60 leukemia cell
line, and found that some of them demonstrated
promising cytotoxicity.
METHODS
Reagents and apparatus
All of the solvents and reagents were obtained com-
mercially and used without further purification. Reac-
tions were monitored by thin-layer chromatography,
using Merck plates. Column chromatography was per-
formed on silica gel.
Melting points were determined with a Yanaco MP-
500D melting point apparatus (Japan) and were uncor-
rected. Nuclear magnetic resonance (NMR) spectra
were recorded on a Bruker Advance DPX-200 FT-NMR
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spectrometer (Bruker Bioscience, Billerica, MA, USA).
Chemical shifts were expressed in ppm using tetram-
ethylsilane as an internal standard. The infrared (IR)
spectra were taken in KBr pellets using a Shimadzu IR
Prestige-21/FTIR-8400 spectrometer (Shimadzu co,
Japan). The ultraviolet (UV) spectra were measured in
methanol with a Hitachi U2800 spectrometer (Tokyo,
Japan). The mass spectra were obtained with VG
Platform II gas chromatography–mass spectrometry or
Finnigan/Thermo Quest MAT 95XL apparatus (–70eV;
Finnigan, USA). Elemental microanalyses were per-
formed by an Elementar vario EL III Heraeus CHNOS
Rapid F002 Analyzer (Heraeus, CHNOS Rapid F002,
Germany) (the elements were within ±0.4% of the the-
oretical values). X-ray diffractometry was performed
by Bruker AXS SMART-1000 (Bruker Bioscience).
Column chromatography was carried out using
Merck Reagents Silica Gel 60 (particle size 0.063–
0.200mm, 70–230 mesh ASTM) (Merck, Germany). The
purity and identity of the compounds were checked
by precoated plates (silica gel 60 F254) purchased from
Merck Inc.
RPMI-1640 medium, fetal bovine serum, L-glu-
tamine and penicillin/streptomycin were obtained
from GIBCO BRL (Grand Island, NY, USA). 3-(4,5-
Dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT), propidium iodide, RNase A and Triton
X-100 were obtained from Sigma Chemical Co. 
(St. Louis, MO, USA).
Preparation of compounds (1)–(8)
9H-pyrido[2,3-b]indole (a-carboline) (1) [17,18]
The mixture of 1H-1,2,3-benzotriazole (3.57g, 0.03mol)
and 2-chloropyridine (5.11 g, 0.045 mol) was heated at
150–160°C for 1 hour. The reaction mixture was cooled
and quenched with 10% Na2CO3 solution. The crude
product was extracted with CHCl3 and washed with
H2O, dried over MgSO4, and evaporated. The residue
was purified by silica gel column chromatography
[n-hexane/ethyl acetate (EtOAc) 4:1] and recrystallized
from n-hexane/ethanol to yield 1-(pyridine-2-yl)-1H-
benzo[d][1,2,3]triazole as a white solid. Yield, 67%;
melting point (mp) 98–100°C; mass: 196 (m/z); found:
C, 67.34; H, 4.11; N, 28.55. C11H8N4 requires: C, 67.33;
H, 4.16; N, 28.49; UV λmax (log ε): 235 (3.79); IR (KBr):
1476 (C = N)/cm; 1H NMR [200 MHz, dimethyl sul-
foxide (DMSO)-d6]: δ 7.47–7.55 (m, 2H), 7.64 (dt, 1H,
J = 1.1, 7.1 Hz), 8.07–8.24 (m, 3H), 8.52 (dd, 1H, J = 0.7,
7.7 Hz), 8.65 (d, 1H, J = 4.9 Hz). 13C NMR (50 MHz,
DMSO-d6): δ 114.7, 114.8, 120.0, 123.6, 125.8, 129.7, 131.3,
140.4, 146.5, 149.2, 151.2. Then, 1-(pyridine-2-yl)-1H-
benzo[d][1,2,3] triazole (5 g, 0.02 mol) and polyphos-
phoric acid (16 g, 0.16 mol) were heated at 150–160°C
until N2 gas evolution ceased, and then heated to
180°C for 15 minutes. After cooling, 5% NaOH solution
(400 mL) was poured into the reaction mixture, and
the precipitate was collected and washed with water.
The crude products were isolated and purified by sil-
ica gel column chromatography (n-hexane/EtOAc 1:1)
and recrystallized from ethanol to give 9H-pyrido
[2,3-b]indole (1) as white needles. Yield, 26%; mp 177–
180°C; mass: 168 (m/z); found: C, 78.55; H, 4.79; N,
16.66. C11H8N2 requires: C, 78.53; H, 4.42; N, 16.91; UV
λmax (log ε): 237 (3.56); IR (KBr): 1457 (C = N)/cm; 1H
NMR (200 MHz, DMSO-d6): δ 7.11–7.17 (m, 2H), 7.40–
7.46 (m, 2H), 8.08 (d, 1H, J = 7.8 Hz), 8.35 (dd, 1H, J =
1.6, 7.7 Hz ), 8.41 (dd, 1H, J = 1.6, 4.8 Hz), 11.77 (s, 1H,
NH).13C NMR (50MHz, DMSO-d6): δ 111.7, 115.4, 115.6,
119.8, 120.8, 121.6, 127.0, 128.8, 139.2, 146.5, 152.3.
6-Acetyl-9H-pyrido[2,3-b]indole (2) [19] and 
8-Acetyl-9H-pyrido[2,3-b]indole (2a)
AlCl3 (0.72 g, 5.4 mmol) and acetyl chloride (0.2 g,
2.4 mmol) at 25 ± 2°C were added to a stirred solution
of compound (1) (0.2 g, 1.2 mmol) in dried CH2Cl2
(20 mL). The mixture was refluxed for 4 hours and
poured into iced water and extracted with EtOAc
(300 mL). The organic layer was washed with water,
dried over MgSO4, and evaporated. The residue was
chromatographed (silica gel/n-hexane/EtOAc) and
recrystallized from ethanol/water to give (2) and (2a).
Compound (2) was white needles. Yield, 62%; mp 232–
234°C; mass: 210 (m/z); found: C, 74.27; H, 4.79; N,
13.33. C13H10N2O requires: C, 74.47; H, 4.69; N, 13.39;
UV λmax (log ε): 236 (3.85); IR (KBr): 1568 (C = N)/cm,
1602, 1667 (C=O)/cm; 1H NMR (200 MHz, DMSO-d6):
δ 2.63 (s, 3H), 7.21 (dd, 1H, J = 4.9, 7.7 Hz), 7.50 (d, 1H,
J = 8.6 Hz), 8.01 (dd, 1H, J = 1.7, 8.6 Hz), 8.41 (dd, 1H, J =
1.6, 4.9 Hz), 8.59 (dd, 1H, J = 1.6, 7.7 Hz), 8.85 (d, 1H,
J = 1.7 Hz), 12.24 (br s, 1H, NH). 13C NMR (50 MHz,
DMSO-d6): δ 27.1, 111.6, 116.0, 116.5, 120.6, 123.4, 127.5
129.5, 129.6, 142.2, 147.3, 152.9, 197.7. Compound (2a)
was yellow–white needles. Yield, 3%; mp 185–186°C;
mass: 210 (m/z); found: C, 74.27; H, 4.79; N, 13.33.
C13H10N2O requires: C, 74.55; H, 4.47; N, 13.42; UV
λmax (log ε): 228 (3.71); IR (KBr): 1667 (C = O)/cm; 1H
NMR (200 MHz, DMSO-d6): δ2.69 (s, 3H), 7.23–7.30
(ddd, 1H, J = 0.8, 4.8, 7.7 Hz), 7.30–7.38 (dt, 1H, J = 0.7,
7.7 Hz), 8.11–8.15 (d, 1H, J = 7.7 Hz), 8.43–8.50 (m, 2H),
8.54–8.59 (d, 1H, J=7.7 Hz), 11.53 (s, 1H, NH). 13C NMR
(50 MHz, DMSO-d6): δ 27.5, 114.7, 116.6, 119.7, 120.5,
122.6, 127.3, 129.4, 129.8, 137.3, 147.4, 152.7, 199.6.
9-Benzyl-9H-pyrido[2,3-b]indole (3)
Benzylbromide (3.56 mmol) was added dropwise to
the stirred solution of compound (1) (0.5 g, 2.97 mmol)
in 11.9 mmol KOH/dehydrated THF, which had been
heated at 50°C for 10 minutes. The reaction mixture was
stirred refluxing for 6 hours and quenched with iced
water. The solid precipitate was extracted with CHCl3,
dried over MgSO4 and evaporated. The residue was
chromatographed (silica gel/n-hexane/EtOAc) and re-
crystallized from ethanol to yield (3) as white needles.
Yield, 53%; mp 101–102°C; mass: 258 (m/z); found: C,
83.69; H, 5.46; N, 10.84. C18H14N2 requires: C, 83.88;
H, 5.48; N, 10.82; UV λmax (log ε): 238 (3.78); IR (KBr):
1740 (C=N)/cm; 1H NMR (200MHz, DMSO-d6): δ 5.67
(s, 2H), 7.20 (m, 7H), 7.40 (t, 1H), 7.56 (d, 1H, J=8.1 Hz),
8.16 (d, 1H, J = 7.8 Hz), 8.45 (d, 1H, J = 4.2 Hz), 8.52 
(d, 1H, J=7.6Hz). 13C NMR (50MHz, DMSO-d6): δ 44.5,
110.6, 116.0, 120.4, 121.3, 127.3, 127.5, 127.7, 129.0, 129.2,
138.2, 139.7, 146.6.
6-Acetyl-9-benzyl-9H-pyrido[2,3-b]indole (4) and 
6-acetyl-1-benzyl-1H-pyrido [2,3-b]indole (4a)
Compound (2) (0.5 g, 2.38 mmol), 9.52 mmol KOH/
dehydrated THF and 2.86 mmol benzyl bromide were
allowed to react as in the preparation of (3), to yield
(4) and (4a). Compound (4) was white needles. Yield,
46%; mp 101–103°C; mass: 300 (m/z); found: C, 79.98;
H, 5.37; N, 9.33. C20H16N2O requires: C, 79.81; H, 5.39;
N, 9.42; UV λmax (log ε): 239 (4.01); IR (KBr): 1662 (C =
O)/cm; 1H NMR (200 MHz, DMSO-d6): δ 2.62 (s, 3H),
5.72 (s, 2H), 7.19 (m, 5H), 7.32 (dd, 1H, J = 4.9, 7.7 Hz),
7.66 (d, 1H, J = 8.7 Hz), 8.03 (dd, 1H, J = 1.7, 8.7 Hz), 8.51
(dd, 1H, J = 1.6, 4.9 Hz), 8.67 (dd, 1H, J = 1.6, 7.7 Hz),
8.90 (d, 1H, J = 1.4 Hz). 13C NMR (50 MHz, DMSO-d6):
δ 27.2, 44.7, 110.4, 116.0, 116.9, 120.2, 123.4, 127.5, 127.8,
129.1, 129.9, 137.8, 142.2, 147.4, 152.1, 197.5. Compound
(4a) was a white solid. Yield, 6%; mp 182–183°C; mass:
300 (m/z); found: C, 79.98; H, 5.37; N, 9.33. C20H16N2O
requires: C, 79.90; H, 5.40; N, 9.37; UV λmax (log ε): 237
(3.99); IR (KBr): 1653 (C = O)/cm; 1H NMR (200 MHz,
DMSO-d6): δ 2.60 (s, 3H), 5.88 (s, 2H), 7.10 (t, 1H), 7.27–
7.43 (m, 5H), 7.59 (d, 1H, J = 8.6 Hz), 7.99 (dd, 1H, J = 1.8,
8.6 Hz), 8.40 (dd, 1H, J=1.0, 5.5 Hz), 8.75 (dd, 1H, J=1.0,
7.1 Hz), 8.85 (d, 1H, J = 1.2 Hz). 13C NMR (50 MHz,
DMSO-d6): δ 27.0, 55.2, 107.4, 109.4, 117.6, 123.1, 123.6,
126.5, 127.8, 128.2, 128.4 (C × 2), 128.5, 129.2 (C × 2),
131.9, 136.0, 136.8, 157.0, 197.3.
6-Acetyl-9-(4-methoxybenzyl)-9H-pyrido[2,3-b]
indole (5)
Compound (2) (0.5 g, 2.38 mmol), 9.52 mmol KOH/
dehydrated THF and 2.86 mmol 4-methoxy benzyl
chloride were allowed to react as in the preparation of
(4), to yield (5) as white needles. Yield, 30%; mp 119–
120°C; mass: 330 (m/z); found: C, 76.34; H, 5.49; N,
8.48. C21H18N2O2 requires: C, 76.38; H, 5.51; N, 8.44; UV
λmax (log ε): 240 (4.03); IR (KBr): 1678 (C = O)/cm; 1H
NMR (200 MHz, DMSO-d6): δ 2.62 (s, 3H), 3.62 (s, 3H),
5.64 (s, 2H), 6.76 (d, 2H, J=8.0Hz), 7.18 (d, 2H, J=8.0Hz),
7.29 (dd, 1H, J=6.0, 8.0 Hz), 7.69 (d, 1H, J=10.0 Hz), 8.04
(dd, 1H, J = 2.0, 10.0 Hz), 8.52 (dd, 1H, J = 2.0, 6.0 Hz),
8.66 (dd, 1H, J = 2.0, 8.0 Hz), 8.89 (d, 1H, J = 2.0 Hz). 13C
NMR (50MHz, DMSO-d6): δ 27.2, 44.2, 55.5, 110.5, 114.4,
116.0, 116.9, 120.2, 123.4, 127.4, 129.0, 129.7, 129.9, 142.1,
147.3, 152.1, 159.0, 197.5.
6-Acetyl-9-(3,5-dimethoxybenzyl)-9H-pyrido[2,3-b]
indole (6)
Compound (2) (0.5 g, 2.38 mmol), 9.52 mmol KOH/
dehydrated THF and 2.86 mmol 3,5-dimethoxybenzyl
bromide were allowed to react as in the preparation
of (4), to yield (6) as white needles. Yield, 31%; mp
145–146°C; mass: 360 (m/z); found: C, 73.32; H, 5.59;
N, 7.77. C22H20N2O3 requires: C, 73.44; H, 5.61; N,
7.75; UV λmax (log ε): 239 (4.08); IR (KBr): 1676 (C =
O)/cm; 1H NMR (200 MHz, DMSO-d6): δ 2.62 (s, 3H),
3.58 (s, 6H), 5.63 (s, 2H), 6.32 (s, 3H), 7.30 (dd, 1H, J =
4.8, 7.7 Hz), 7.66 (d, 1H, J = 8.7 Hz), 8.04 (dd, 1H, J = 1.7,
8.7 Hz), 8.50 (dd, 1H, J=1.6, 4.8 Hz), 8.67 (dd, 1H, J=1.6,
7.7 Hz), 8.90 (d, 1H, J = 1.5 Hz). 13C NMR (50 MHz,
DMSO-d6): δ 27.2, 44.8, 55.5, 98.9, 105.7, 110.5, 115.9,
116.9, 120.2, 123.4, 127.5, 130.0, 140.1, 142.3, 147.4, 152.1,
161.1, 197.5.
6-Acetyl-9-(3,4,5-trimethoxybenzyl)-9H-pyrido[2,3-b]
indole (7)
Compound (2) (0.5 g, 2.38 mmol), 9.52 mmol KOH/
dehydrated THF and 2.86mmol 3,4,5-trimethoxybenzyl
chloride were allowed to react as in the preparation of
(4), to yield (7) as white needles. Yield, 23%; mp 149–
151°C; mass: 390 (m/z); found: C, 70.75; H, 5.68; N,
7.17. C23H22N2O4 requires: C, 70.77; H, 5.77; N, 7.20;
UV λmax (log ε): 239 (4.06); IR (KBr): 1667 (C = O)/cm;
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1H NMR (200 MHz, DMSO-d6): δ 2.63 (s, 3H), 3.52 (s,
3H), 3.57 (s, 6H), 5.62 (s, 2H), 6.64 (s, 2H), 7.32 (dd, 1H,
J=4.8, 7.7Hz), 7.76 (d, 1H, J=8.7Hz), 8.05 (dd, 1H, J=1.5,
8.7 Hz), 8.53 (dd, 1H, J=1.4, 4.8 Hz), 8.67 (dd, 1H, J=1.4,
7.7 Hz), 8.89 (d, 1H, J = 1.2 Hz). 13C NMR (50 MHz,
DMSO-d6): δ 27.2, 45.1, 56.2, 60.4, 105.3, 110.5, 116.0,
116.9, 120.2, 123.4, 127.5, 129.9, 133.4, 137.3, 142.3, 147.3,
152.1, 153.4, 197.5.
9-Benzyl-6-(1-hydroxyethyl)-9H-pyrido[2,3-b]indole (8)
Compound (3) (0.5 g, 1.6 mmol) was added to a solu-
tion of 32 mmol NaBH4 in dehydrated methanol, stir-
red at 25°C for 24 hours, and quenched with iced
water. The solid precipitate was extracted with CH2Cl2,
dried over MgSO4, and evaporated. The residue was
purified by column chromatography (n-hexane/EtOAc
1:1) and recrystallized from n-hexane/EtOAc to yield
9-benzyl-6-(1-hydroxyethyl)-9H-pyrido[2,3-b]indole
(8) as a white solid. Yield, 29%; mp 86–87°C; mass:
302 (m/z); found: C, 79.44; H, 6.00; N, 9.26. C20H18N2O
requires: C, 79.38; H, 6.09; N, 9.33; UV λmax (log ε): 239
(3.76); IR (KBr): 3362 (OH)/cm; 1H NMR (200 MHz,
DMSO-d6): δ 1.34 (d, 1H, J = 6.4 Hz), 4.81 (q, 1H, J =
6.3Hz), 5.14 (d, 1H, J=3.6Hz), 5.65 (s, 2H), 7.14 (m, 6H),
7.39 (dd, 1H, J = 1.4, 8.5 Hz), 7.48 (d, 1H, J = 8.4 Hz), 8.14
(s, 1H), 8.42 (dd, 1H, J = 1.5, 4.8 Hz), 8.51 (dd, 1H, J = 1.5,
7.6Hz). 13C NMR (50MHz, DMSO-d6): δ 26.8, 44.5, 68.9,
110.1, 115.7, 115.9, 118.4, 121.1, 125.2, 127.5, 127.7, 128.9,
129.0, 138.3, 138.5, 139.9, 146.4.
Human leukemia HL-60 cell line and 
cell culture
Human leukemia HL-60 cells were obtained from the
American Type Culture Collection (Manassas, VA,
USA). Cells were cultured in RPMI-1640 medium sup-
plemented with 10% fetal bovine serum, penicillin
(100 U/mL)/streptomycin (10 μg/mL), and 1% L-
glutamine at 37°C in a humidified atmosphere of 5%
CO2. Cells were split every day to maintain the cell
numbers between 2 and 5 × 105 cells/mL. The cell
numbers were assessed by the standard procedure of
leukocyte counting using a hemocytometer.
Antiproliferative analysis
HL-60 cells were seeded at a density of 1 × 105 cells/
mL in 24-well culture plates and treated with test
compounds for 48 hours. All of the test compounds
were dissolved in DMSO, and the final concentration
of DMSO in the culture medium was kept below
0.1%. The antiproliferative effect was assessed using
the MTT assay, as described below. The inhibitory con-
centration (IC) was determined by plotting compound
concentration versus cell viability. The half maximal
IC (IC50) value was then calculated.
MTT assay
We added 10 μL MTT solution (5 mg/mL) with 50 μL
cell suspension in Hank’s Balanced Salt Solution to a
96-well plate, which was incubated at 37°C in the dark
for 4 hours. Treatment of living cells with MTT pro-
duced a dark blue formazan product, whereas no such
staining was observed in dead cells. The formazan
product was dissolved by adding 150 μL DMSO and
the absorbance was measured on an enzyme-linked
immunosorbent assay reader at a best wavelength of
570 nm.
Flow cytometric analysis of DNA content
for cell cycle
To estimate the effect of various concentrations of
compound (7) on the proportion of HL-60 cells in dif-
ferent phases of the cell cycle, cellular DNA content
was measured by flow cytometry. Cells (2 × 105/well)
were treated for 12 hours with or without various con-
centrations of compound (7). Cells were fixed with
70% ethanol overnight at 4°C, washed twice, and re-
suspended in PBS that contained 20 μg/mL propid-
ium iodide, 0.2 mg/mL RNase A and 0.1% of Triton
X-100 in a dark room. After 30 minutes at 37°C incu-
bation, the cell cycle distribution was analyzed using
ModFit LT Software (Verity Software House, Topsham,
USA) in BD FACSCanto flow cytometer (Becton
Dickinson, San Jose, CA).
RESULTS AND DISCUSSION
Chemistry
As shown in Scheme 1, the starting α-carboline (1) was
prepared according to published methods [17,18],
and acetylated by the method of Cédric [19] to yield
products (2) and (2a), which were found to have the
same molecular formula C13H10N2O by mass spectro-
scopy and elemental analysis. The chemical structure
of the major product (2) (62%) was determined by 1H
NMR spectrum as 6-acetyl-9H-pyrido[2,3-b]indole,
which was the same product reported by Cédric. On
the other hand, the analysis of various NMR spectra
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Scheme 1. Reagents and conditions: (a) AlCl3/CH2Cl2, (b) KOH/THF, (c) NaBH4/MeOH.
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Figure 1. Atom arrangements and numbering for compound 2a.
(1H NMR, heteronuclear multiple quantum correlation
and heteronuclear multiple bond correlation) could not
unambiguously determine whether the minor prod-
uct (2a) (3%) was a 5- or 8-acetyl derivative. Finally,
X-ray diffractometry assigned its structure as 8-acetyl-
9H-pyrido[2,3-b]indole (Figure 1). Table 1 reports crys-
tal data and refinement results for (2a), and selected
geometric parameters are listed in Tables 2 and 3.
Separately, compound (1) was benzylated by reacting
with benzyl bromide in THF, in the presence of KOH,
and 9-benzyl-9H-pyrido[2,3-b]indole (3) was obtained.
However, when compound (2) was subjected to alky-
lation by reacting with benzyl bromide in THF, in the
presence of KOH, two products, (4) and (4a), were
isolated. The elemental analysis and mass spectra of
both products were consistent with a molecular for-
mula of C20H16N2O, which indicated that they were
isomers of benzylation products. Based on the 1H
NMR analysis, the major product (4) was assigned as
6-acetyl-9-benzyl-9H-pyrido[2,3-b]indole. The struc-
ture of the minor product (4a) was determined to be
6-acetyl-1-benzyl-1H-pyrido[2,3-b]indole by the cor-
relation between the –CH2-Ph (δ 55.17) and H-2 (δ 8.40)
signals in its heteronuclear multiple bond correlation
spectrum. Following the same synthetic procedure for
compound (4), three other substituted benzyl deriva-
tives (5–7) were prepared, although their accompany-
ing minor products were not intentionally isolated.
Compound (4) was reduced with NaBH4 to its corre-
sponding alcohol (8).
Cytotoxicity activity
All of the above synthesized α-carboline derivatives
(1–8) were evaluated for cytotoxicity against the 
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Table 2. Selected bond lengths for 2a
Atoms Bond lengths (Å)
O-C(7) 1.222(3)
N(1)-C(2) 1.374(3)
N(1)-C(10) 1.398(2)
N(1)-H(1A) 0.8800
N(2)-C(10) 1.332(3)
N(2)-C(13) 1.358(2)
C(3)-C(4) 1.388(3)
C(3)-C(2) 1.416(3)
C(3)-C(9) 1.446(3)
C(1)-C(6) 1.389(3)
C(1)-C(2) 1.409(3)
C(1)-C(7) 1.473(3)
C(4)-C(5) 1.384(3)
C(4)-H(4A) 0.9500
C(5)-C(6) 1.403(3)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.509(3)
C(8)-H(8A) 0.9800
C(8)-H(8B) 0.9800
C(8)-H(8C) 0.9800
C(9)-C(11) 1.370(3)
C(9)-C(10) 1.412(3)
C(11)-C(12) 1.397(3)
C(11)-H(11A) 0.9500
C(12)-C(13) 1.378(3)
C(12)-H(12A) 0.9500
C(13)-H(13B) 0.9500
Table 1. Crystal data and refinement results for com-
pound (2a)
Identification code 2a
Empirical formula C13H10N2O
Formula weight (g/mol) 210.23
Temperature 100(2) K
Wavelength 0.71073 Å
Crystal system Monoclinic
Space group P21/n
Unit cell dimensions
a (Å) 11.6087 (8)
b (Å) 5.3734 (3)
c (Å) 15.4052 (9)
β° 92.075 (6)
Volume (Å3) 960.31 (10)
Z 4
Density (calculated) (mg/m3) 1.454
Absorption coefficient, 0.095
μ (mm–1)
F(000) 440
Crystal size 0.20 mm3 × 0.10 mm3 ×
0.10 mm3
T range (°) 3.51–29.05
Index ranges –15 ≤ h ≤ 13, –7 ≤ k ≤ 6, 
–20 ≤ l ≤ 20
Reflections collected/ 4,557 / 2,210 (0.0555)
unique (Rint)
T Completeness (°) 99.8% (26)
Absorption correction Semi-empirical from 
equivalents
Maximum and minimum 0.9906 and 0.9813
transmission
Refinement method Full-matrix least-squares 
on F2
Data/restraints/parameters 2210/3/145
Goodness-of-fit on F2 0.684
Final R indices [I > 2σ(I)] R1 = 0.0450, wR2 = 0.0593
R indices (all data) R1 = 0.1386, wR2 = 0.0684
Largest diff. peak and 0.238 and –0.234
hole (e.Å–3)
HL-60 leukemia cell line. As shown in Table 4, the non-
substituted α-carboline (1) had almost no cytotoxicity
(IC50 >100μM). However, the introduction of an acetyl
group into its 6-position resulted in compound (2),
with a dramatic increase of inhibitory activity against
HL-60 cells (IC50 = 15.9 μM). Its positional isomer (2a),
however, exhibited poor cytotoxicity (IC50 > 50 μM).
The introduction of a benzyl group into the 9-position
(3) of compound (1) resulted in significantly increased
inhibitory activity, although not as potent as that of
compound (2). Our attempt to introduce 6-acetyl and
9-benzyl groups simultaneously onto and α-carboline
scaffold yielded compound (4) with an IC50 = 2.3 μM.
When the 9-benzyl of compound (4) was moved to the
1-position (4a) or 6-acetyl group of compound (4) was
reduced to alcohol (8), the anti-cancer activity was
decreased.
Synthesis and cytotoxicity of a-carbolines
Kaohsiung J Med Sci November 2010 • Vol 26 • No 11 599
Table 4. Cytotoxicity of 1,6,8,9-substituted-α-carbolines
(1–8)
No. R6 R8 R9 IC50 (μM)
1 H H H > 100
2 COCH3 H H 15.9
2a H COCH3 H > 50
3 H H 26.3
4 COCH3 H 2.3
4a - - - 34.9
8 C(CH3)HOH H 33.9
5 COCH3 H 8.8
6 COCH3 H 0.06
7 COCH3 H 0.03
*HL-60 cells (1 × 105/mL) were treated with tested samples for
48 hours. IC50 = half maximal inhibitory concentration.
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
H3C
O
N
N
N
N
R9
R6
R8
4a1–8
Table 3. Selected bond angles for 2a
Atoms Angles (°)
C(2)-N(1)-C(10) 108.71(19)
C(2)-N(1)-H(1A) 125.6
C(10)-N(1)-H(1A) 125.6
C(10)-N(2)-C(13) 112.65(18)
C(4)-C(3)-C(2) 120.4(2)
C(4)-C(3)-C(9) 132.6(2)
C(2)-C(3)-C(9) 107.0(2)
C(6)-C(1)-C(2) 117.0(2)
C(6)-C(1)-C(7) 121.5(2)
C(2)-C(1)-C(7) 121.4(2)
N(1)-C(2)-C(1) 130.2(2)
N(1)-C(2)-C(3) 109.0(2)
C(1)-C(2)-C(3) 120.8(2)
C(5)-C(4)-C(3) 119.4(2)
C(5)-C(4)-H(4A) 120.3
C(3)-C(4)-H(4A) 120.3
C(4)-C(5)-C(6) 119.9(2)
C(4)-C(5)-H(5A) 120.0
C(6)-C(5)-H(5A) 120.0
C(1)-C(6)-C(5) 122.4(2)
C(1)-C(6)-H(6A) 118.8
C(5)-C(6)-H(6A) 118.8
O-C(7)-C(1) 121.0(2)
O-C(7)-C(8) 119.8(2)
C(1)-C(7)-C(8) 119.2(2)
C(7)-C(8)-H(8A) 109.5
C(7)-C(8)-H(8B) 109.5
H(8A)-C(8)-H(8B) 109.5
C(7)-C(8)-H(8C) 109.5
H(8A)-C(8)-H(8C) 109.5
H(8B)-C(8)-H(8C) 109.5
C(11)-C(9)-C(10) 118.32(19)
C(11)-C(9)-C(3) 135.5(2)
C(10)-C(9)-C(3) 106.13(18)
N(2)-C(10)-N(1) 124.2(2)
N(2)-C(10)-C(9) 126.69(19)
N(1)-C(10)-C(9) 109.10(18)
C(9)-C(11)-C(12) 117.1(2)
C(9)-C(11)-H(11A) 121.4
C(12)-C(11)-H(11A) 121.4
C(13)-C(12)-C(11) 119.5(2)
C(13)-C(12)-H(12A) 120.2
C(11)-C(12)-H(12A) 120.2
N(2)-C(13)-C(12) 125.67(19)
N(2)-C(13)-H(13B) 117.2
C(12)-C(13)-H(13B) 117.2
The symmetry transformations used to generate equivalent
atoms are bracketed.
We then focused on structural modification of the
benzyl group of compound (4). First, addition of a
methoxy group at the para position of the benzyl
group (5) resulted in reduced cytotoxicity. On the
contrary, introduction of two methoxy groups onto
both meta positions of the benzyl group (6) resulted
in markedly enhanced cytotoxicity (IC50 = 0.06 μM).
The introduction of an additional methoxy group
onto the para position of benzyl group (7) resulted in
further enhanced cytotoxicity (IC50 = 0.03 μM). Both
compounds (6) and (7) are potent α-carboline deriva-
tives and deserve further investigation.
Effects of various concentrations of
compound 7 on G2/M arrest of HL-60 cells
To determine the stage at which compound-7-induced
growth inhibition occurs in the cell cycle progression
of HL-60 cells, flow cytometric analysis was con-
ducted. As shown in Figure 2, compound-7-treated
cells showed a pattern of DNA content together with
a sub-G1 phase (apoptotic cells). Compound 7 in-
creased the number of cells in G2/M phase from
12.88% to 62.20%, and increased apoptosis from 1.48%
to 23.38%, in a dose-dependent manner.
In conclusion, we have synthesized a series of α-
carboline derivatives based on sequential introduc-
tion of acetyl and substituted benzyl groups onto the
1-, 6-, 8- and 9-positions. These compounds were eval-
uated for their cytotoxicity against the HL-60 cell line.
Compounds (6) and (7) demonstrated potent cyto-
toxicity, and were identified as new lead compounds
for further development as anticancer drugs. Besides,
we chose compound (7) to determine its mechanism
of cytotoxicity against HL-60 cells, and found that it
had an obvious effect on G2/M cell cycle arrest. The
detailed mechanism of action of compound (7) will
be explored further.
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12 hours, harvested, and analyzed by flow cytometry.
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1,6,8,9- 取代 -α- 咔吧 衍生物之合成與
細胞致毒活性
蔡睿盈  林怡倩  徐美華  郭盛助  黃麗嬌
中國醫藥大學  藥學院  藥物化學研究所
α-咔吧 （吡啶駢 [2,3-b]吲 ）經由結構上的修飾被選擇當做開發抗血癌藥物之基
本骨架。從其結構抗癌活性研究發現，將乙醯基及取代芐基導入α-咔吧 基本骨架
的第六位及第九位中，所得到的 6-乙醯基 -9-(3,5-二甲氧基芐基 )-9H-吡啶駢 [2,3-b]
吲 (6) 及 6-乙醯基 -9-(3,4,5-三甲氧基芐基 )-9H-吡啶駢 [2,3-b]吲 (7) 對 HL-60血
癌細胞株具有優異的細胞致毒活性。這兩個化合物將作為新型先導藥物及進一步的研
究。
關鍵詞：抗血癌藥物，α-咔吧 ，HL-60，結構 -活性關係
（高雄醫誌 2010;26:593–602）
